Literature DB >> 21907910

Experimental challenges to targeting poorly characterized GPCRs: uncovering the therapeutic potential for free fatty acid receptors.

B D Hudson1, Nicola J Smith, Graeme Milligan.   

Abstract

The G protein-coupled receptors (GPCRs) are extremely successful drug targets, with recent estimates suggesting that approximately 30% of all currently available therapeutics act at these receptors. Despite this success, only a small number of the over 400 known nonodorant GPCRs are currently targeted, suggesting there is still untapped therapeutic potential. However, as most GPCRs were identified based on their sequence homology to other members of the superfamily, many still remain "orphan" receptors without known ligands. Indeed, even once a GPCR has been deorphanized, the receptor typically is still poorly characterized in terms of its pharmacology and biological functions, presenting a unique set of experimental challenges in order to define its therapeutic potential. We discuss some of these challenges and how they have been addressed in order to uncover the therapeutic potential of five recently deorphanized receptors that are activated by short- and long-chain free fatty acids.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907910     DOI: 10.1016/B978-0-12-385952-5.00006-3

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN: 1054-3589


  23 in total

Review 1.  Role of Short Chain Fatty Acid Receptors in Intestinal Physiology and Pathophysiology.

Authors:  Medha Priyadarshini; Kumar U Kotlo; Pradeep K Dudeja; Brian T Layden
Journal:  Compr Physiol       Date:  2018-06-18       Impact factor: 9.090

Review 2.  Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4.

Authors:  G Milligan; E Alvarez-Curto; K R Watterson; T Ulven; B D Hudson
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

3.  Orphans to the rescue: orphan G-protein coupled receptors as new antidepressant targets.

Authors:  Paul R Albert
Journal:  J Psychiatry Neurosci       Date:  2020-09-01       Impact factor: 6.186

Review 4.  Drugs or diet?--Developing novel therapeutic strategies targeting the free fatty acid family of GPCRs.

Authors:  H J Dranse; M E M Kelly; B D Hudson
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

Review 5.  Bitter taste receptors on airway smooth muscle as targets for novel bronchodilators.

Authors:  Stephen B Liggett
Journal:  Expert Opin Ther Targets       Date:  2013-04-12       Impact factor: 6.902

6.  Drug discovery opportunities and challenges at g protein coupled receptors for long chain free Fatty acids.

Authors:  Nicholas D Holliday; Sarah-Jane Watson; Alastair J H Brown
Journal:  Front Endocrinol (Lausanne)       Date:  2012-01-03       Impact factor: 5.555

7.  The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism.

Authors:  Brian D Hudson; Bharat Shimpukade; Amanda E Mackenzie; Adrian J Butcher; John D Pediani; Elisabeth Christiansen; Helen Heathcote; Andrew B Tobin; Trond Ulven; Graeme Milligan
Journal:  Mol Pharmacol       Date:  2013-08-26       Impact factor: 4.436

8.  Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets.

Authors:  Trond Ulven
Journal:  Front Endocrinol (Lausanne)       Date:  2012-10-02       Impact factor: 5.555

9.  Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs.

Authors:  Brian D Hudson; Elisabeth Christiansen; Irina G Tikhonova; Manuel Grundmann; Evi Kostenis; David R Adams; Trond Ulven; Graeme Milligan
Journal:  FASEB J       Date:  2012-08-23       Impact factor: 5.191

10.  Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3.

Authors:  Brian D Hudson; Irina G Tikhonova; Sunil K Pandey; Trond Ulven; Graeme Milligan
Journal:  J Biol Chem       Date:  2012-10-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.